Loading
A phase 1/2 trial of ABX196 in hepatocellular carcinoma, run by Abivax S.A., now recruiting.
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT03897543 by Abivax S.A., with 48 participants planned, started 2019-08-30 and due to reach its primary completion in 2021-06-30. Interventions recorded: ABX196.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Hepatocellular carcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/